{
  "topicName": "Neuropathic pain - drug treatment",
  "topicId": "35e3d915-8243-4418-a7dd-6590d8ca5c85",
  "exportId": "805be768-a1aa-470a-af6b-aa5700e2147d",
  "dataId": "e9636bea-6d62-4a63-9d48-aa5b00cd4619",
  "number": 4,
  "dateOfExport": "2019-05-28T12:27:21.7427192+00:00",
  "nextPlannedReviewBy": "2020-12-31T23:59:59+00:00",
  "topicSummary": "Neuropathic pain is a symptom that develops as a result of damage to, or dysfunction of, the nervous system.",
  "lastRevised": "Last revised in May&nbsp;2019",
  "terms": [
    {
      "code": "D009437",
      "term": "Neuralgia"
    }
  ],
  "clinicalSpecialties": [
    "Drugs and devices",
    "Neurological"
  ],
  "topicHtmlObjects": [
    {
      "itemId": "08a7d0f6-02a3-4246-956b-762d4cd722dd",
      "parentId": null,
      "rootId": "08a7d0f6-02a3-4246-956b-762d4cd722dd",
      "fullItemName": "Summary",
      "htmlHeader": "<!-- begin field 232d2bea-0e56-45b0-8bd2-82a411273941 --><h1>Neuropathic pain - drug treatment: Summary</h1><!-- end field 232d2bea-0e56-45b0-8bd2-82a411273941 -->",
      "htmlStringContent": "REPLACE_ON_SERVE",
      "containerElement": "topicSummary",
      "children": [],
      "depth": 1,
      "pos": 0
    }
  ],
  "latestChanges": [
    {
      "dateFrom": "2019-05-01T00:00:00+01:00",
      "dateTo": "2019-05-31T23:59:59+01:00",
      "title": "Minor update",
      "body": "Dysphagia added as an adverse effect of gabapentin."
    },
    {
      "dateFrom": "2019-03-01T00:00:00+00:00",
      "dateTo": "2019-03-31T23:59:59+01:00",
      "title": "Minor update",
      "body": "Gabapentin and pregabalin have now be rescheduled as Schedule 3 Controlled Drugs NHS England, 2019."
    },
    {
      "dateFrom": "2018-10-01T00:00:00+01:00",
      "dateTo": "2018-10-31T23:59:59+00:00",
      "title": "Minor update",
      "body": "References to amitriptyline being off-label removed."
    },
    {
      "dateFrom": "2017-09-01T00:00:00+01:00",
      "dateTo": "2017-09-30T23:59:59+01:00",
      "title": "Minor update",
      "body": "Change to adverse effects for gabapentin to reflect changes to the manufacturer&#39;s Summary of Product Characteristics regarding respiratory disorders."
    },
    {
      "dateFrom": "2017-07-01T00:00:00+01:00",
      "dateTo": "2017-07-31T23:59:59+01:00",
      "title": "Minor update",
      "body": "Addition to adverse effects for pregabalin to reflect changes to the manufacturer&#39;s Summary of Product Characteristics."
    },
    {
      "dateFrom": "2015-06-01T00:00:00+01:00",
      "dateTo": "2015-06-30T23:59:59+01:00",
      "title": "Minor update",
      "body": "Based on an update to the manufacturer&#39;s Summary of Product Characteristics, hyponatraemia has been included as a possible adverse effect of gabapentin ABPI 2015."
    },
    {
      "dateFrom": "2014-06-01T00:00:00+01:00",
      "dateTo": "2014-06-30T23:59:59+01:00",
      "title": "Minor update",
      "body": "Update to the text to reflect the fact that tramadol has been reclassified to a schedule 3 controlled drug."
    },
    {
      "dateFrom": "2014-01-01T00:00:00+00:00",
      "dateTo": "2014-02-28T23:59:59+00:00",
      "title": "Reviewed",
      "body": "A literature search was conducted in January 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. The following changes were made:"
    }
  ]
}